Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study

Breast Cancer Research and Treatment

Volumn 135, Issue 2, 2012, Pages 611-618

  Li, Christopher I ^a   Mirus, Justin E ^a   Zhang, Yuzheng ^a   Ramirez, Arturo B ^a   Ladd, Jon J ^a   Prentice, Ross L ^a   McIntosh, Martin W ^a   Hanash, Samir M ^a   Lampe, Paul D ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Biomarkers; Breast cancer; Early detection; Triple negative

Indexed keywords

BIOLOGICAL MARKER; JANUS KINASE; STAT PROTEIN;

ADULT; AFRICAN AMERICAN; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY MASS; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DOWN REGULATION; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNIC DIFFERENCE; FEMALE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; HISPANIC; HUMAN; JAK GENE; OBESITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PYRIMIDINE METABOLISM; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; STAT GENE; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; VALIDATION STUDY;

AGED; AREA UNDER CURVE; BREAST NEOPLASMS; CASE-CONTROL STUDIES; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; PROTEIN ARRAY ANALYSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; WOMEN'S HEALTH;

EID: 84866538209     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2204-4     Document Type: Article

References (35)

1. Bebenek M, Dus D, Kozlak J (2006) Fas and Fas ligand as prognostic factors in human breast carcinoma. Med Sci Monit 12:CR457-CR461 (Pubitemid 44736927)
2. Bebenek M, Dus D, Kozlak J (2007) Fas/Fas-ligand expressions in primary breast cancer are significant predictors of its skeletal spread. Anticancer Res 27:215-218 (Pubitemid 46363334)
3. Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V (2008) The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptornegative, invasive breast cancer: the California Cancer Registry, 1999-2004. Cancer 112:737-747 (Pubitemid 351240567)
4. Campbell TN, Attwell S, Arcellana-Panlilio M, Robbins SM (2006) Ephrin A5 expression promotes invasion and transformation of murine fibroblasts. Biochem Biophys Res Commun 350:623-628 (Pubitemid 44547894)
5. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492-2502 (Pubitemid 43854964)
6. Collett K, Stefansson IM, Eide J, Braaten A, Wang H, Eide GE, Thoresen SO, Foulkes WD, Akslen LA (2005) A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 14:1108-1112 (Pubitemid 40656455)
7. Dunnwald LK, Rossing MA, Li CI (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 9:R6
8. Gaudet MM, Press MF, Haile RW, Lynch CF, Glaser SL, Schildkraut J, Gammon MD, Douglas TW, Bernstein JL (2011) Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. Breast Cancer Res Treat 130:587-597
9. Hays J, Hunt JR, Hubbell FA, Anderson GL, Limacher M, Allen C, Rossouw JE (2003) The Women's Health Initiative recruitment methods and results. Ann Epidemiol 13:S18-S77 (Pubitemid 37324176)
10. Kalin M, Cima I, Schiess R, Fankhauser N, Powles T, Wild P, Templeton A, Cerny T, Aebersold R, Krek W, Gillessen S (2011) Novel prognostic markers in the serum of patients with castrationresistant prostate cancer derived from quantitative analysis of the pten conditional knockoutmouse proteome. Eur Urol 60:1235-1243
11. Kaplan HG, Malmgren JA (2008) Impact of triple negative phenotype on breast cancer prognosis. Breast J 14:456-463
12. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G (2006) Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neuoverexpressing phenotypes. Hum Pathol 37:1217-1226 (Pubitemid 44286991)
13. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750-2767
14. Loch CP, Ramirez AB, Liu Y, Sather CL, Delrow JJ, Scholler N, Garvik GM, Urban ND, McIntosh MW, Lampe PD (2007) Use of high density antibody arrays to validate and discover cancer serum biomarkers. Mol Oncol 1:313-320 (Pubitemid 350181643)
15. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O'Regan RM, Gabram SG, Eley JW (2009) Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 113:357-370
16. Ma H, Wang Y, Sullivan-Halley J, Weiss L, Marchbanks PA, Spirtas R, Ursin G, Burkman RT, Simon MS, Malone KE, Strom BL, McDonald JA, Press MF, Bernstein L (2010) Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study. Cancer Res 70:575-587
17. Metzger-Filho O, Tutt A, de AE, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA, Jr., Ellis P, Di LA, Baselga J, Sotiriou C, Piccart-Gebhart M (2012) Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol (In press)
18. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L (2009) Screening for breast cancer: an update for the U.S. preventive services task force. Ann Intern Med 151:727-742
19. Omenn GS (2004) The human proteome organization plasma proteome project pilot phase: reference specimens, technology platform comparisons, and standardized data submissions and analyses. Proteomics 4:1235-1240 (Pubitemid 38648012)
20. Perou CM, Sorlie T, Eisen MB, van de RM, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406:747-752
21. Phipps AI, Buist DS, Malone KE, Barlow WE, Porter PL, Kerlikowske K, Li CI (2011) First-degree family history of breast cancer and triple-negative breast cancer risk. Breast Cancer Res Treat 136:671-678
22. Phipps AI, Chlebowski R, Prentice R, McTiernan A, Wactawski-Wende J, Kuller LH, Adams-Campbell LL, Lane D, Stefanick ML, Vitolins M, Kabat GC, Rohan TE, Li CI (2010) Reproductive history and oral contraceptive use in relation to risk of triplenegative breast cancer. J Natl Cancer Inst (In press)
23. Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Stefanick ML, Wactawski-Wende J, Kuller LH, Adams-Campbell LL, Lane D, Vitolins M, Kabat GC, Rohan TE, Li CI (2011) Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev 20:454-463
24. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI (2008) Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 17:2078-2086
25. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI (2008) Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer 113:1521-1526
26. Porter PL, El-Bastawissi AY, Mandelson MT, Lin MG, Khalid N, Watney EA, Cousens L, White D, Taplin S, White E (1999) Breast tumor characteristics as predictors of mammographic detection: comparison of interval-and screen-detected cancers. J Natl Cancer Inst 91:2020-2028
27. Rakha EA, Reis-Filho JS, Ellis IO (2008) Basal-like breast cancer: a critical review. J Clin Oncol 26:2568-2581
28. Ramirez AB, Lampe PD (2010) Discovery and validation of ovarian cancer biomarkers utilizing high density antibody microarrays. Cancer Biomark 8:293-307
29. Ramirez AB, Loch CM, Zhang Y, Liu Y, Wang X, Wayner EA, Sargent JE, Sibani S, Hainsworth E, Mendoza EA, Eugene R, Labaer J, Urban ND, McIntosh MW, Lampe PD (2010) Use of a single-chain antibody library for ovarian cancer biomarker discovery. Mol Cell Proteomics 9:1449-1460
30. Scholler N, Gross JA, Garvik B, Wells L, Liu Y, Loch CM, Ramirez AB, McIntosh MW, Lampe PD, Urban N (2008) Use of cancer-specific yeast-secreted in vivo biotinylated recombinant antibodies for serum biomarker discovery. J Transl Med 6:41
31. Smyth GK, Speed T (2003) Normalization of cDNA microarray data. Methods 31:265-273 (Pubitemid 37338763)
32. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8418-8423 (Pubitemid 36842560)
33. The Women's Health Initiative Study Group (1998) Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 19:61-109
34. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, Parnes HL, Coltman CA Jr (2005) Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294:66-70 (Pubitemid 41002840)
35. White DE, Kurpios NA, Zuo D, Hassell JA, Blaess S, Mueller U, Muller WJ (2004) Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 6: 159-170 (Pubitemid 39485688)